Kinaset Therapeutics is developing KN-002, a non-invasive inhaled therapeutic that delivers anti-inflammatory agents directly to the lungs, targeting severe asthma regardless of the inflammation's underlying cause. This approach minimizes systemic exposure while addressing the unmet medical need for effective treatments in patients with intractable respiratory diseases.
Funding
$68.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Severe asthma patients often face limited treatment options that effectively target inflammation in the lungs, regardless of the underlying cause. Current therapies may not adequately address the unmet medical need for those with intractable respiratory diseases.
Solution
Kinaset Therapeutics is developing KN-002, an inhaled therapeutic designed to deliver anti-inflammatory agents directly to the lungs. This non-invasive approach aims to minimize systemic exposure while maximizing the drug's impact on the site of inflammation. By targeting the root cause of inflammation in the lungs, KN-002 seeks to provide a more effective treatment option for all patients with severe asthma, irrespective of the specific inflammatory pathway involved. The inhaled delivery method offers a convenient and targeted approach to managing severe asthma symptoms.
Target Audience
The primary target audience includes patients with severe asthma and healthcare professionals specializing in respiratory diseases.
Features
- Non-invasive inhaled delivery for targeted drug administration to the lungs.
- Anti-inflammatory agents designed to address inflammation regardless of its underlying cause.
- Minimized systemic exposure to reduce potential side effects.
- Formulation specifically designed for patients with severe asthma.